Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 101 to 110 of 220 total matches.
Cannabis and Cannabinoids
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
, and generics; Syndros) and
nabilone (Cesamet) are synthetic forms of THC indicated
for chemotherapy-induced ...
Cannabis (marijuana) contains more than 60
pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
are the best known. THC is the main psychoactive
constituent of cannabis. CBD, unlike THC, does not
produce intoxication or euphoria.
Darbepoetin (Aranesp) - A long-acting Erythropoietin
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001 (Issue 1120)
− A double-blind study in 320 patients with lung cancer receiving chemotherapy
found that darbepoetin SC ...
Darbepoetin alfa (Aranesp) has been approved by the FDA for treatment of anemia caused by chronic renal disease and will probably also be approved for use in patients with cancer..
Trimetrexate
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989 (Issue 784)
responders (B Akil et al, 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles ...
Trimetrexate glucuronate (Parke-Davis), an investigational drug, is now available in the USA from the National Institute of Allergy and Infectious Diseases (NIAID) for treatment of selected AIDS patients with Pneumocystis carinii pneumonia (PCP). For this indication, trimetrexate is always used concurrently with leucovorin (Wellcovorin; and others).
Ifosfamide and Mesna
The Medical Letter on Drugs and Therapeutics • Nov 03, 1989 (Issue 804)
) for concurrent use with
other drugs in third-line chemotherapy of metastatic germ-cell testicular cancer. Given ...
Ifosfamide (Ifex - Mead Johnson), a synthetic analog of cyclophosphamide (Cytoxan; and others), has been approved by the US Food and Drug Administration (FDA) for concurrent use with other drugs in third-line chemotherapy of metastatic germ-cell testicular cancer. Given concomitantly, a synthetic sulfhydryl compound known as mesna (Mesnex - Asta) acts in the urine to detoxify metabolites of ifosfamide that cause hemorrhagic cystitis (H Burkert, Cancer Treat Rev, 10 suppl A:175, 1983). Ifosfamide and mesna are available together from Bristol-Myers Oncology Division.
BCG For Bladder Cancer
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991 (Issue 841)
cystectomy for complete eradication; a minority respond to intravesical
chemotherapy, but usually ...
BCG Live (TheraCys - Connaught) and BCG Vaccine U.S.P. (TiceBCG - Organon), freeze-dried suspensions of an attenuated strain of Mycobacterium bovis, were recently approved by the US Food and Drug Administration for intravesical treatment of primary or relapsed carcinoma in situ of the bladder, with or without associated papillary tumors. BCG is not recommended for treatment of papillary tumors occurring alone.
Altretamine For Ovarian Cancer
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991 (Issue 850)
, 10:827, 1990).
CLINICAL TRIALS — As A Single Agent − Standard first-line chemotherapy for ovarian ...
Altretamine (Hexalen - US Bioscience; Hexastat - Rh ne-Poulenc in Canada), formerly known only by its chemical name, hexamethylmelamine, was recently approved by the US Food and Drug Administration as a single agent for palliative oral treatment of persistent or recurrent ovarian cancer.
Enzalutamide (Xtandi) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Mar 04, 2013 (Issue 1411)
, and their tumors eventually become resistant to
hormone treatment. Docetaxel-based chemotherapy,
abiraterone ...
The FDA has approved enzalutamide (en za loo’ ta
mide; Xtandi – Astellas/Medivation) for oral treatment
of metastatic castration-resistant prostate cancer in
patients previously treated with docetaxel (Taxotere,
and generics). It is the second oral drug approved for
this indication; abiraterone acetate (Zytiga), which is
also approved for first-line use, was the first.
Cabazitaxel (Jevtana), which is given parenterally, has
a similar indication.
Ziv-Aflibercept (Zaltrap) for Metastatic Colorectal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 29, 2013 (Issue 1415)
to chemotherapy, is a standard firstand
second-line therapy.2,3
these results compare to those achieved ...
Ziv-aflibercept (Zaltrap – Sanofi/Regeneron), a vascular
endothelial growth factor (VEGF) inhibitor, has
been approved by the FDA for use in combination with
5-fluorouracil, leucovorin and irinotecan (FOLFIRI) for
treatment of metastatic colorectal cancer that is resistant
to or has progressed following an oxaliplatin-containing
regimen. It is the same drug as aflibercept,
which was approved last year as an intravitreal injection
(Eylea) for treatment of neovascular (wet) agerelated
macular degeneration (AMD). Ziv-aflibercept
is the second VEGF inhibitor approved for treatment...
Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
and/or chemotherapy,
is the treatment of choice for localized soft-tissue
sarcoma. Doxorubicin with or without ...
Olaratumab (Lartruvo – Lilly), a platelet-derived growth
factor receptor alpha (PDGFR-α) blocking monoclonal
antibody, has received accelerated approval from the
FDA for use in combination with the anthracycline
doxorubicin for first-line treatment of adults with
soft-tissue sarcoma histologic subtypes considered
susceptible to anthracyclines. Approval is limited to
locally advanced or metastatic soft-tissue sarcomas
that are not amenable to curative radiotherapy or
surgery, and is contingent on verification of clinical
benefit in a confirmatory phase 3 trial.
Atezolizumab (Tecentriq) for Alveolar Soft Part Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
resection and platinum-based
chemotherapy in adults with stage II to IIIA NSCLC whose tumors
express PD-L1 ...
Atezolizumab (Tecentriq – Genentech), an immune
checkpoint inhibitor, has been approved by the FDA
for treatment of unresectable or metastatic alveolar
soft part sarcoma (ASPS) in patients ≥2 years old. It
was previously approved for treatment of non-small
cell lung cancer, small cell lung cancer, hepatocellular
cancer, and melanoma (see Table 1). Atezolizumab is
the first drug to be approved in the US for treatment
of ASPS. ASPS is a rare disorder that affects mostly
adolescents and young adults; <1% of soft tissue
sarcomas are ASPS.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e56-7 doi:10.58347/tml.2023.1673d | Show Introduction Hide Introduction